{"id":"tx200-tr101","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T06:44:47.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:51:19.454715+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05987527","phase":"","title":"Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sangamo Therapeutics","startDate":"2023-08-15","conditions":"Kidney Transplant Rejection, End Stage Renal Disease","enrollment":11},{"nctId":"NCT04817774","phase":"PHASE1, PHASE2","title":"Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sangamo Therapeutics","startDate":"2021-03-17","conditions":"Kidney Transplant Rejection, End Stage Renal Disease","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAR-Tregs"],"phase":"phase_1","status":"active","brandName":"TX200-TR101","genericName":"TX200-TR101","companyName":"Sangamo Therapeutics","companyId":"sangamo-therapeutics","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:51:19.454715+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}